Format

Send to

Choose Destination
Urology. 1999 Jun;53(6):1126-32.

Male urethral carcinoma: analysis of treatment outcome.

Author information

1
Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.

Abstract

OBJECTIVES:

To evaluate our experience with primary carcinomas of the male urethra and to analyze the impact of tumor variables and treatment on overall, disease-specific, local recurrence-free, and metastasis-free survival.

METHODS:

Between 1958 and 1996, we identified 46 men with primary carcinoma of the bulbar and anterior urethra. The median follow-up was 125 months (1 to 336). The patients were stratified by stage, nodal status, histologic type, treatment, type of surgery, site of disease, year at diagnosis, and smoking status.

RESULTS:

The overall survival and disease-specific survival rates at 5 years were 42% and 50%, respectively. The recurrence-free survival and metastasis-free survival rates at 5 years were 51% and 56%, respectively. The overall survival rate was 83% for superficial disease versus 36% for invasive tumors. The overall survival rate was 26% for tumors of the bulbar urethra versus 69% for tumors of the anterior urethra.

CONCLUSIONS:

Current modalities of treatment are ineffective for local control and survival. New treatment strategies are needed for urethral cancer.

PMID:
10367840
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center